Related by context. All words. (Click for frequent words.) 73 results 62 Preliminary Results 60 Findings 56 Result 56 Match Fixtures 56 Results Exceed Expectations 54 Earnings Release Schedule 54 Wrestling Wrap Up 54 Earnings 53 Significant assay 53 Grouped Hockey 53 Results Confirm 53 Taping Results SPOILERS 53 Projected Release Date 53 TOFUTTI Announces 52 Adtegrity.com Reports 52 Statutory Accounts 52 2nd Quarter Results 52 Financial Results 52 RESULTS 51 Operational Results 51 First Quarter Results 51 Quarter Results 51 XPEL Announces 50 Preliminary 50 Figures 50 Third Quarter Results 50 EPS Excl 50 1st Quarter Results 50 BioSante Pharmaceuticals Reports 49 resutls 49 Reiterates Guidance 49 -6News Jennifer 49 Cash Dividend Declared 49 Encision Reports 49 Predictive Value 49 Topline Results 49 Innovium Announces 49 Fourth Quarter Results 49 Positive Results 49 Pro Forma EPS 49 Highlights 49 Results Indicate 49 BRIM3 49 Earnings Release Webcast 48 Dividend Announcement 48 Second Quarter Results 48 3rd Quarter Results 48 Spectrum Pharmaceuticals Announces 48 Outpatient Setting 48 Results Release Date 48 Significant mineralized intercepts 48 Kerala SSLC 48 Pharmacokinetic 48 Irvine Sensors Releases 48 Survey Findings 48 Updates Guidance 48 Results Reflect 47 Confirms Guidance 47 multicenter multinational 47 R# #mg BID 47 MERIT ES 47 x denotes seeding 47 Karnataka SSLC 47 Bladex Announces 47 TriMas Corporation Announces 47 Improved Second Quarter 47 Earnings Release Scheduled 47 Pharmacokinetic parameters 47 Result Declared 47 Ameris Bancorp Reports 47 Narrows Quick Facts 47 MEDTOX Scientific Announces 47 Nine Month 47 Clinical Trial Results 47 Univest Corporation Declares 47 Schedules 2Q 47 Lupus Drug 47 Insteel Industries Announces 47 Bakers Footwear Reports 47 SPIRIT FIRST 46 Confirmatory 46 PremierWest Bancorp Announces 46 ROCA Reports 46 Increases Guidance 46 Fully Diluted Earnings Per 46 Releases Second Quarter 46 Trans Lux Reports 46 Clinical Trial Data 46 Narrows Loss 46 Earnings Per Diluted 46 Primary Endpoint 46 Largely Unchanged 46 -Krefeld Germany 46 Unaudited Fourth Quarter 46 Assay Results 46 Telik Announces 46 Negative Symptom Scale PANSS 46 Statistically Significant 46 PSEB 8th 46 Preclinical Study 46 Substantially Improved 46 Preliminary Second Quarter 46 Inter Citic Reports 46 Thallion Announces 46 resuts 46 BlogPoll Ballot 46 SCHEDULED TO PREMIERE 46 Significant Improvement 46 Loss Shrinks 46 Assay results 46 JNTU Kakinada 46 Nordson Corporation Declares 46 Techni lab 46 PetroQuest Energy Announces 46 Positive Scoping Study 46 Oral Fingolimod 46 caustic fusion diamond 46 Files Restated 46 Net Loss Narrows 46 Habersham Bancorp Announces 46 Earnings Webcast 46 Hemodialysis Patients 46 Teleconference Announcement 45 Record Second Quarter 45 Widens Loss 45 PCI ExTRACT TIMI 45 specified secondary endpoints 45 Qtrly Avg 45 Kaydon Corporation Announces 45 Phase IIB 45 Announces Profitable 45 Posts Fourth Quarter 45 Sono Tek Announces 45 HORIZONS AMI trial 45 Preliminary metallurgical 45 -#:# GMT/# 45 Significant intersections 45 Cites Positive 45 Plumas Bancorp Reports 45 Reaffirms Guidance 45 Randomized Trials 45 Achieves Record Production 45 Irvine Sensors Sets 45 Exceeds Guidance 45 http:/news.yahoo.com/polls 45 F#Q# Earnings 45 FINANCIAL RESULTS 45 Statistics TEAM STATISTICS 45 holes #WR# 45 Loss Widened 45 Contract Signings 45 JNTU Anantapur 45 Earnings Surge 45 Items impacting comparability 45 geochemical assay 45 Viad Corp Announces 45 Pro Forma Results 45 Highlights Include 45 downhole radiometric logging 45 ACR# responses 45 Macy KB Toys 45 Incr 45 Revises Third Quarter 45 Comparability 45 Valhi Reports 45 Operating Results 45 Higher Than Expected 45 Reports Significantly Improved 45 Tallies 45 Idenix Pharmaceuticals Reports 45 Slight Increase 45 Widths 45 Posts Impressive 45 Significant intercepts 45 SABESP Announces 45 Losses Narrow 45 Showed Significant 45 Exam Results 45 Winmark Corporation Announces 45 Capacity FVC 45 Outcome 45 QHR Announces 45 BioFuel Reports 45 IMPACT DCM 45 Synalloy Corporation Announces 45 Eighth Consecutive 45 Cashflow Report 45 Meets Expectations 45 Loss Narrowed 45 Posts Solid 45 Q4 F# 45 Aromatase Inhibitors 45 Posts Profitable 45 PPD Declares 45 Phase 2b monotherapy 44 Earnings Release Date 44 WSB Qualifying 44 Delivers Strong 44 GetGoal Phase III 44 Patients Receiving 44 Vicon Reports 44 Guidance Quick Facts 44 Significant Increase 44 Survival Benefit 44 Audited 44 FFO Declines 44 Exam Result 44 Tesmilifene 44 SEACOR Holdings Announces 44 Combination REOLYSIN R 44 Profit Grows 44 First Patient Enrolled 44 Q2 FY# [001] 44 Stent Thrombosis 44 Kronos Worldwide Reports 44 Revises Guidance 44 Results Teleconference 44 Goodwill Impairment Charge 44 Castration Resistant Prostate Cancer 44 Losses 44 Examination Result 44 Revenues 44 Pacific Rubiales Announces 44 Profits 44 Scores 44 Assays 44 Pharmacodynamic 44 Widens Quick Facts 44 Newfield Provides 44 Earnings Decline 44 Revises Full 44 LifeVantage Announces 44 Survival Rates 44 Orckit Communications Reports 44 Infill Drilling 44 NSABP B 44 Tikcro Technologies Reports 44 Drill Hole Results 44 Drill Intercepts 44 Dia Bras Announces 44 Quarter Fiscal 44 evaluating mipomersen 44 eOn Communications Reports 44 HemaCare Reports 44 Efficacy Results 44 Preliminary Third Quarter 44 LEAP GEE 44 Post hoc 44 Consolidated Cash Flows 44 SVR# 44 Net Loss Widens 44 Trenching Results 44 Performance Metrics 44 FY# Guidance 44 Saehan Bancorp Reports 44 Comorbidities 44 Multicenter Phase 44 HCV RESPOND 2 44 microdiamond results 44 drilling wireline logs 44 Losses Widen 44 Virco Announces 44 Extendicare REIT Announces 44 Exceeds Expectations 44 -Lighting Designers 44 Shows Efficacy 44 Salix Pharmaceuticals Announces 44 Reports Profitable 44 -ANDREA SACHS 44 Subgroup analysis 44 Nymox Reports 44 1st Quarter Earnings 44 Drug Fails 44 Catastrophe Losses 44 Earnings Announcement Date 44 Jennifer Convertibles Reports 44 Delivers Solid 44 Histopathological 44 Statistically Significant Improvement 44 Eagerly Awaiting 44 Mineralized intercepts 44 Guidance Raised 44 Completes Patient Enrollment 44 Low Voter Turnout 44 Measurements 44 Profit Surged 44 Posts Strong 44 AVN# Phase 44 Assay Results From 44 Posts Gains 44 Histological 44 Record Third Quarter 44 Oncotype DX ® 44 Significant Assay Results 44 Recurrent Prostate Cancer 43 Quarter Fiscal Year 43 refractory acute lymphoblastic 43 WWE Smackdown Spoilers 43 Skin Irritation 43 Cash Flow Positive 43 Backs FY# 43 Profitable Quarter 43 Pooled Analysis 43 Subgroup Analysis 43 Crowflight Announces 43 exploratory endpoints 43 Revenues Decline 43 TriCo Bancshares Announces 43 Hovnanian trims 43 Releases Third Quarter 43 Supplemental Financials 43 Bingo.com Announces 43 Cin FG Graham 43 Raloxifene STAR 43 Oil Dri Announces 43 Antitumor Activity 43 Margin Improvement 43 Aircastle Announces 43 Net Profit Triples 43 #RB# 43 Randomized Controlled Trials 43 ANCOVA 43 Net Loss 43 Shows Promising 43 Placebo Controlled Trial 43 Meets Estimates 43 Meta analyzes 43 widens Quick Facts 43 AMERISAFE Announces 43 reults 43 Improves Outcomes 43 Earnings Teleconference 43 Webcast Scheduled 43 Exceed Estimates 43 Posts 4Q 43 AZCAR Announces 43 Heart Failure Therapies 43 IDEXX Laboratories Announces 43 Posts Third Quarter 43 Third Qtr 43 Metallurgical Testing 43 Macusani Yellowcake Announces 43 ACR# ACR# 43 prefix denotes seeding 43 Randomized Clinical Trials 43 Posts Wider Loss 43 DEBD 43 Ejection Fraction 43 Histologic 43 Net Profit Drops 43 EastGroup Properties Announces 43 Summaries 43 Profit Slumps 43 Nortech Systems Reports 43 Fiscal Second Quarter 43 Study Showed 43 Texas Instruments Narrows 43 RTI Biologics Announces 43 holes #RB# 43 ENDEAVOR III 43 Delays Filing 43 Profit Fell 43 virological response 43 NYMAGIC INC. Reports 43 Stereotaxis Announces 43 ESCO Announces 43 Platelet Inhibition 43 Reaffirms Outlook 43 CHMP Opinion 43 Exceed Guidance 43 Exceptional Items 43 Items Affecting 43 ANNOUNCES FIRST QUARTER 43 randomized Phase 2b 43 Profitable Second Quarter 43 Bankruptcy Filings Up 43 Pennichuck Corporation Announces 43 Highlights Achieved 43 Univariate analysis 43 BIOLASE Announces 43 unaudited Consolidated Statement 43 Fourth Qtr 43 Tovaxin Phase IIb 43 Revenue Climbs 43 Unaudited Third Quarter 43 Outcome Measures 43 Histopathologic 43 Profit Edges Up 43 Productivity Rises 43 TAXUS ATLAS 43 Summary CONDENSED CONSOLIDATED 43 4th Qtr 43 Cause Mortality 43 Comparatives 43 Profitable Third Quarter 43 Revised Guidance 43 Second Quarter Ended 43 Drilling Activity 43 Order Intake 43 Fiscal Third Quarter 43 Monthly Fact Sheet 43 Qrtr 43 hematological parameters 43 Sees 3Q 43 angiographic outcomes 43 Q#/FY# 43 Kidney Function 43 Wizzard Software Announces 43 Quarter Earnings 43 Proginet Announces 43 Profits Jump 43 2Q 1Q 43 Improves Survival 43 Audited Financials 43 Lifts FY# Earnings 43 Revenue Grows 43 * SPOILERS * 43 Intervention Trial 43 -Lake Andrusia 43 prospective observational cohort 43 Net Profit Soars 43 Upcoming Milestones 43 Quarter Earnings Release 43 FOLPI 42 Non Recurring Items 42 Radiation Doses 42 Results Disappoint 42 VP# [004] 42 Sangamo BioSciences Announces 42 Relapsing Remitting Multiple Sclerosis 42 Unaudited Second Quarter 42 RECORD1 42 RIO Lipids 42 ACCORD COPD 42 Fifth Consecutive 42 Study Shows Significant 42 Highest Ever 42 Revises Fourth Quarter 42 Regular Quarterly 42 Newly Diagnosed Multiple Myeloma 42 Anti Tumor Activity 42 Reschedules Second Quarter 42 Minera IRL Announces 42 Measurement Specialties Announces 42 ABCSG 42 Profit Quadruples 42 Has Been Announced 42 Oral Glucose Tolerance 42 Breast Exams 42 -dwayne tingley 42 Profitability Ratios 42 Cogdell Spencer Earnings 42 Secondary endpoints 42 narrows Quick Facts 42 BRIM2 42 Reported Earnings Per 42 -Peter Van Keuren 42 Localized Prostate Cancer 42 Loss Narrows Quick Facts 42 Phase III Pivotal Trial 42 Biopsies 42 -Edgewater Networks 42 Vyvx Advertising Distribution 42 Improved Survival 42 Fiscal Quarter Results 42 Preclinical Data 42 SSLC Results 42 Affirms FY# 42 undetectable HBV DNA 42 Pivotal Study 42 Stent Restenosis 42 Anticipates Record 42 -Union BHCAWU 42 Drill Results 42 Data Suggest 42 Seventh Consecutive 42 Generates Record 42 HARRIS CORPORATION FY'# 42 Third Consecutive Quarter 42 Prognostic Value 42 captioned Factors Affecting 42 Patient Outcomes 42 fidaxomicin Phase 42 Remains Flat 42 IBERIABANK Corporation Reports 42 Commence Immediately 42 Univariate 42 Quarterly 42 Coronary Artery Calcium 42 EINSTEIN DVT 42 Quarterly Dividend Payment 42 KRAS status 42 Yearend 42 Summarizes 42 Randomized Double Blind 42 4Q Profit Slides 42 Randomised Trial 42 Positive Cash Flow 42 Gastrointestinal Stromal Tumors 42 Meets Primary Endpoint 42 SIGNIFICANT ACCOUNTING POLICIES 42 Active Ulcerative Colitis 42 Stent Implantation 42 Raises FY# EPS 42 Over Unders 42 Randomised 42 Oceaneering Announces 42 Summary Table 42 Hold Third Quarter 42 phase IIIb 42 Tops Ests 42 3q 42 Literacy Test OSSLT 42 Statistical Summary 42 Tightens FY# 42 Q#/# Q#/# Q#/# Q#/# [001] 42 Statistical Supplement Operating 42 Loss Widens Quick Facts 42 Revises Q4 42 Vancocin R 42 Pharmacokinetic PK 42 Non GAAP Consolidated Statements 42 Correlation Between 42 www.BankAtlanticBancorp.com 42 Announces Monthly Distributions 42 Profits Climb 42 Viral Suppression 42 Tumor Response 42 Profit Plummets 42 Revenues Increase 42 Tops Expectations 42 Study Validates 42 Posts 2Q 42 Drill Intersections 42 Grinding Wheels 42 unaudited consolidated balance sheets 42 Profit Triples 42 Outcomes 42 Below Expectations 42 Profit Leaps 42 evaluating Prochymal 42 Improved Profitability 42 REPORTS THIRD QUARTER 42 TRANSFORMS 42 Urine Test 42 multicenter randomized controlled 42 Schizophrenia Treatment 42 Audited Results 42 Period Ending 42 Stockholder Vote 42 Sequential Quarter 42 Backs FY# Outlook 42 Ambulatory Blood Pressure 42 Reveals Significant 42 Supplementary Appendix 42 Brentuximab Vedotin SGN 42 Main Outcome Measures 42 Southwall Announces 42 Metastatic Renal Cell Carcinoma 42 Demonstrates Positive 42 Complete Remission 42 Profit Dips 42 Anworth Announces 42 Narrows Guidance 42 Net Profit Jumps 42 duplex ultrasonography 42 ASCO GU 42 Genotypes 42 Q1 Adj 42 ± SD 42 Pro Forma Consolidated Statements 42 Schweitzer Mauduit Announces 42 Resource Calculation 42 Zacks Estimate 42 Profits Dip 42 OYO Geospace Reports 42 Bracket Updates 42 Confirms Efficacy 42 Stays Strong 42 Lung Cancer Detection 42 Profit Rises Quick Facts 42 Sirolimus Eluting 42 thefourth quarter 42 hole DDH# 42 Double Digit Earnings 42 Shareholder Letter 42 Sequential Increase 42 DAVANAT R exhibits 42 Current Beneficiary 42 Recurrence 42 Second Quarter Dividend 42 Reschedules Fourth Quarter 42 DXP Enterprises Announces 42 Consolidated Condensed Statement 42 Data Indicates 42 Guides FY# 42 3rd Quarter Earnings 42 CONSOLIDATED RESULTS 42 Posts Narrower Loss 42 Profit Tumbles 42 Sentinel Lymph Node Biopsy 42 Reports Narrower 42 Issues Guidance 42 Live Stream Updates 42 Phase 2b Study 42 Treatment Outcome 42 Record Fourth Quarter 42 Conclusive 42 Adverse Event 42 Relapsed Multiple Myeloma 42 Webcast Third Quarter 42 Study Demonstrates 42 Exit Polls 42 Provides Updated 42 Main Event UNOFFICIAL 42 Hypertension Diagnostics Announces 42 multivariable adjusted 42 Late Breaker 42 Guidance Guidance 42 * Denotes [002] 42 HCV SPRINT 42 findings 42 relapsed MM 42 Reported 42 Randomized controlled 42 FFO Rises 41 Elbit Imaging Announces 41 Help Predict 41 quantitative RT PCR 41 Webcast Fourth Quarter 41 APTIMA HPV assay 41 Q# Q# Q# 41 Adjuvant Treatment 41 Inventory Levels 41 Antipsychotic Drugs 41 Randomized Study 41 ViRexx Announces 41 Achieves Positive 41 Partners LP Declares 41 Income Rises 41 Schedules 41 EUR -#.# [001] 41 prospective multicentre 41 Initiated Phase 41 Mineralized intersections 41 Profit Declines Quick Facts 41 completely resected 41 Double Blind Placebo 41 Boosts 1Q Profit 41 MEND CABG 41 Dose Escalation 41 ssc result 41 Earnings Rise 41 metabolite concentrations 41 AvalonBay Communities Announces 41 Half Yearly Report 41 Phase 2b randomized 41 Achieves Primary Endpoint 41 Long Term Outcomes 41 Oroco Announces 41 CAMMS# 41 Net Income 41 Earnings Soar 41 Milestone Payment 41 PreCISe 41 Detrex Corporation Reports 41 SABCS 41 Posts Narrower 41 www.cbseresults.nic.in 41 Randomized Phase 41 Cuts FY# EPS 41 Inflammatory Markers 41 Randomized Controlled 41 WDD# 41 Tops Estimate Update 41 Consensus Estimate 41 Topics Covered Executive 41 Coronary Artery Bypass Graft 41 Profits Surge 41 Reduces Quick Facts 41 Gerdau Ameristeel Announces 41 Hematological Cancers 41 Fourth Quarter Earnings Per 41 Phase Ib Clinical Trial 41 Slight Improvement 41 Prostate AdenoCarcinoma Treatment 41 Pre RELAX AHF 41 Receives Favorable 41 AND FOURTH QUARTER 41 #WR# 41 MAG Silver Reports 41 SF #v# 41 Reaffirms Full 41 AVADO 41 BLUE SPRINGS BUDDY BASS 41 AirBoss Announces 41 NLX P# 41 Clinical Remission 41 Lowers FY# EPS 41 Lung Cancer Survival 41 Consolidation Continues 41 Underlying Pretax 41 Significantly Improves 41 Profits Drop 41 Gastar Exploration Announces 41 2nd Quarter Earnings 41 Backs FY# Earnings 41 Items Affecting Comparability 41 Phase III Trial 41 Q2 Loss Per 41 PreCISe study 41 Profit Slides 41 1Q 2Q 41 Randomized Clinical Trial 41 Quality Indicators 41 Revises FY# 41 Observations 41 Genetic Defect 41 CLARITY study 41 Prognostic Significance 41 GeoPharma Announces 41 Posts 3Q 41 CALERIE 41 AND TACKLE 41 Backs FY# Forecast 41 1Q Profits 41 Job Vacancies 41 Cystatin C 41 Rheumatoid Arthritis Patients 41 Local ScoreBoard 41 Summarized below 41 Latest Updates 41 Backs FY# EPS 41 lithological controls 41 Phase 2b Clinical Trial 41 Extreme Ripoff 41 Immediately Accretive 41 Profit Beats Views 41 Significant Improvements 41 BRE Properties Announces 41 Testing Finds 41 Highest Scoring 41 Nicotine Vaccine 41 Primary endpoints 41 FFO Rises Quick 41 exponential regression 41 Forecast Predicts 41 Flamel Technologies Announces 41 Multiple Myeloma Patients 41 Uncertainty Surrounds 41 Successfully Completed 41 Drug Coated Stents 41 Simulations Plus Reports 41 Bracketed figures 41 Brain Scans 41 Updates FY# EPS 41 Levels Linked 41 Adjuvant Chemotherapy 41 SUMMARY OF OPERATING RESULTS 41 Fiscal Quarter Earnings 41 Arctic Glacier Posts 41 Operational Highlights 41 PGECET 41 Analyses 41 Cholesterol Drugs 41 Multiple Ascending Dose 41 Stronger Than Expected 41 Loss Reduces 41 Immunogenicity 41 Digimarc Schedules 41 Upcoming Investor Presentations 41 Profit Gains 41 Provides Update Regarding 41 Profit Surges 41 4Q Loss Widens 41 Profit Climbs 41 multivariate analyzes 41 Breakdown Summary 41 audited audited 41 Loss Narrows 41 www.crai.com 41 1Q Earnings 41 Third Quarter Nine Months 41 Announce Shareholder Approval 41 Havertys Reports 41 Alexco Announces 41 Profit Sinks 41 Data Extraction 41 Plus Ribavirin 41 Lymph Nodes 41 Sequential Growth 41 Asset Impairment Charge 41 Profit Plunges 41 ATAC Arimidex Tamoxifen Alone 41 Down Slightly 41 Restate Prior 41 Dose Finding 41 Revises Q3 41 Sees 2Q 41 #Q'# #Q'# #Q'# #Q'# 41 Profit Skyrockets 41 Restate Past 41 Carotid Artery Stenting 41 Drug Candidate 41 1st Qtr 41 VIVUS Announces 41 Relapsing Multiple Sclerosis 41 HRQL 41 Multivariate analysis 41 Respiratory Viruses 41 GRAVITAS trial 41 ARRIVE 41 Adherex Reports 41 Subgroup analyzes 41 Profits Rise 41 Misys Healthcare Experience 41 Summary RECONCILIATION OF 41 Sees 1Q Profit 41 Surpass Expectations 41 Consumer Confidence Slips 41 Dips Slightly 41 Announces Rescheduling 41 -hologram stickers 41 Boosts Profit 41 Echocardiographic 41 HER2 overexpressing 41 MANAGEMENT DISCUSSION AND ANALYSIS 41 adding AJAX widgets 41 Secondary efficacy endpoints 41 Comp Store 41 BUSINESS SEGMENT INFORMATION 41 Guidelines Issued 41 REPORTS SECOND QUARTER 41 Second Quarter 41 bevirimat Study 41 COPERNICUS 41 Quickie Statistics 41 Serious adverse reactions 41 Volume Detected 41 meta regression 41 Profit Soars 41 Profits Decline 41 downhole gamma logging 41 Calgon Carbon Announces 41 Drilling Intersects 41 Revises Second Quarter 41 3Q Earnings 41 DCE MRI 41 Second Quarter Earnings Announcement 41 Narrower Loss 41 Earnings Guidance 41 Annulled 41 Bulk Tonnage 41 Renal Cell Carcinoma RCC 41 Medoro Resources Announces 41 Maximum Tolerated Dose 41 Cheal A6 41 Blood Pressure Drugs 41 Accelr8 Announces 41 Endocrine Society #st 41 Patterson UTI Reports 41 Earnings Climb 41 Cognitive Function 41 MOCON Announces 41 http:/www.ap-gfkpoll.com 41 Weaker Than Expected 41 Surpasses Expectations 41 GAAP Adj 41 Achieves Record Sales 41 More Than Doubled 41 geological mapping trenching 41 Oral Anticoagulants 41 Reaches Profitability 41 Victories 41 º #-#/# reports 41 Controlled Trial 41 Statin Drugs 41 IGM TSX IGM 41 Testwork 41 EDAC Technologies Reports 41 Adjusted Earnings 41 Epidemiologic studies 41 OPERATING SEGMENTS 41 geochemical geophysical 41 Study Indicates 41 Carotid Revascularization Endarterectomy vs. 41 Drug Reactions 41 Matrix Phase 2b 41 Sees 4Q Profit 41 spirometric 41 non GAAP Measures 41 Quarter Ended Ended 41 Profit Little Changed 41 ALISTA 41 Carotid Endarterectomy 41 Quarter Ending 41 Got Kicked Off 41 Below Estimates 41 Growth Seen Slowing 41 Dialysis Outcomes 41 Lower Than Expected 41 Mineral Resource Estimation 41 www.results.nic.in 41 BHEM surveys 41 Ajmer Chennai 41 Earnings Preview Activision Blizzard 41 3Q 2Q 41 FINANCIAL REVIEW 41 Completes Airborne 41 HREO TREO 41 IAROC 41 PROTECT AF 41 Three Months Ending 41 mean ± SEM 41 Newmont Declares Regular 41 Pivotal Phase III 41 Guidance Reaffirmed 41 Angiographic 41 SuperMedia specializes 41 Severity MSCS score 41 Serious Adverse Events 41 Significantly Improved 41 Achieves Record Results 41 Few Surprises 41 End Earnings Release 41 immunohistochemical analysis 41 THIRD QUARTER HIGHLIGHTS 41 mineralogical analysis 41 -Abdul Shukor Husin 41 Profit Doubles 41 Poniard Pharmaceuticals Announces 41 Helps Detect 41 NDA Submission 41 PERSEUS 41 Reports Third Consecutive 41 baseline FEV 40 PROSTVAC VF 40 Respiratory Symptoms 40 Randomized Phase III 40 Sustained Efficacy 40 Gene Mutations 40 First Quarter 40 Preliminary Assessment Study 40 Immunomedics Announces 40 Schedules Earnings Release 40 Technological Advances 40 4Q 3Q 40 Radical Prostatectomy 40 Raises Full 40 REPORTS FIRST QUARTER 40 Supplemental Schedules 40 Overwhelming Support 40 Webcast Second Quarter 40 SUCCEED trial 40 Undertakes 40 Insulin Therapy 40 Consecutive Quarters 40 Beats Estimate 40 Q3 Profit Plunges 40 Hotly Contested 40 Worse Than Expected 40 Study Underscores 40 Toromont Announces 40 Losses Deepen 40 Decline Slightly 40 Trading Volumes 40 Outlook Remains 40 Detect Lung Cancer 40 NQ diamond 40 Underlying EBIT 40 Expands Scope 40 Rulings 40 LaCrosse Footwear Announces 40 3Q Pft 40 TAXUS ARRIVE 40 Lowers 1Q 40 unaudited Consolidated Statements 40 Snowfall Impact 40 Diagnostic Criteria 40 Further Validates 40 Q3 Loss Per 40 4th Qtr 4th Qtr 40 Phase 1b clinical trials 40 bronchial lavage 40 bepotastine besilate nasal spray 40 Per Share Quarter Ended 40 3rd Quarter 40 AUDIOCODES LTD 40 XTENT Announces 40 Spherix Announces 40 Phase Ib II 40 Edge STudy 40 Predict Response 40 ORACLE MS 40 Updates Fourth Quarter 40 FDA Okays 40 Airborne geophysical surveys 40 #m@#.#g t [001]